CDI Global
Login
Person name

Gary Epler

CDI Global Partner

Experience & Qualifications

Experience & Qualifications

 

Gary R. Epler, M.D., is a partner at CDI Global North America, with extensive experience in M&A with a focus on healthcare including MedTech, medical devices, biotech and genomics diagnostics, and specialty pharma.

 

Dr. Gary Epler is an internationally known Harvard Medical School professor and bestselling author who has impacted the lives of people throughout the world through his speaking engagements, six health books, teaching, and consulting. He has been called upon by individuals from around the globe who have a rare lung disease called BOOP that he discovered. He has developed the "Eplerian Philosophy" which is a modern-day way of life for people to live their best lives at home, at work, and in society defined as “know who you are moment by moment.” He has worked at the Centers for Disease Control (CDC) in Atlanta; discovered a lung fluke parasite in Colombia, South America; and was Chairman, Department of Medicine. He has been recognized yearly since 1994 in The Best Doctors in America and one of Boston Magazine’s “Top Doctors in Town.” He is a radio and television personality, and a Hollywood screenwriter for a medical thriller movie. Dr. Epler is a successful serial entrepreneur as a founder and CEO of three companies including a biotech company, a nutraceutical company, and a health management company. Dr. Epler is an award-winning speaker, addressing audiences about health, productivity, and leadership.

 

Dr. Gary Epler can be reached at gary.epler@cdiglobal.com or at + 1 617 680 0650.

Connect with a CDI Expert. Request a Call Back.

News & Insights

Read more

November 27, 2024

De-risking or Doubling Down? Strategic Alternatives for German Chemical Companies in China

Read more

November 20, 2024

How we see the personal care industry in the next 5 years

1
The Agro-Industrial Sector Worldwide Challenge
2
RGS Partners | Success Story – RGS Partners ranked #1
3
Case study: When your growth business model stalls to a halt